Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987438 | 1.00 | PTGS2 (0.48) | PTGS2ESR2 | |
| SCHEMBL4367492 | 0.89 | PTGS2 (0.47) | PTGS2ESR2 | |
| SCHEMBL4367496 | 0.89 | PTGS2 (0.47) | PTGS2ESR2 | |
| SCHEMBL4367488 | 0.88 | PTGS2 (0.46) | PTGS2ESR2 | |
| SCHEMBL6150553 | 0.88 | PTGS2 (0.51) | PTGS2ESR2 | |
| SCHEMBL3987417 | 0.87 | PTGS2 (0.47) | PTGS2ESR2 | |
| SCHEMBL3987412 | 0.87 | PTGS2 (0.47) | PTGS2ESR2 | |
| SCHEMBL3480237 | 0.85 | PTGS2 (0.40) | PTGS2ESR2 | |
| SCHEMBL4423118 | 0.85 | PTGS2 (0.40) | PTGS2ESR2 | |
| SCHEMBL3480240 | 0.85 | PTGS2 (0.40) | PTGS2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622502-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-7622502-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| EP-1601644-B1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080227758-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors | BERTHELETTE CARL | 2008-09-18 | — | — | US | disclosed |
| US-20080227758-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors | BERTHELETTE CARL | 2008-09-18 | — | — | US | disclosed |
| EP-1711457-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1711459-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711457-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| EP-1601644-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070874-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070883-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| EP-1527045-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004103955-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2004-12-02 | — | — | WO | disclosed |
| US-20040176331-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2004-09-09 | — | — | US | disclosed |
| WO-2004011421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176331-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885ESR2 1609/4885 |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885ESR2 1536/4885 |
| US-20080227758-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885ESR2 1631/4885 |
| US-20050261245-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885ESR2 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.